4-Fluoroamphetamine (4-FA) is a fluorinated analog of amphetamine in which a fluorine atom occupies the 4-position (para) of the phenyl ring. It is classified simultaneously as an Entactogen and Stimulant, reflecting a dose-dependent dual pharmacological profile: at lower doses (50–100 mg) it produces primarily stimulant effects comparable to amphetamine, while at higher doses (100–200 mg) a significant entactogenic component emerges, producing empathy, emotional warmth, and mild MDMA-like sociability. This MDMA-adjacent profile at typical doses made 4-FA uniquely popular in the Netherlands, where it was used widely as a "safer MDMA alternative" — particularly after it remained unscheduled while MDMA remained illegal.
The para-fluorine substitution at the 4-position dramatically increases 4-FA's serotonin releasing activity compared to 2-FA or 3-FA, producing an effect profile distinct from any other common fluorinated amphetamine. Community experience consistently describes the full-dose 4-FA experience as a cleaner, longer, and less physically taxing entactogen than MDMA, with more prominent stimulant character and a reportedly milder comedown. Duration is typically 5–7 hours — longer than MDMA but shorter than 2-FMA or 3-FPM.
The widespread use of 4-FA in the Netherlands came to an abrupt end following a series of serious adverse events — including cases of hypertensive crisis and at least several deaths — linked to 4-FA use in 2017–2018, leading to emergency scheduling. These events established that despite its reputation as "gentler" than MDMA, 4-FA carries significant cardiovascular and neurotoxic risks, particularly at higher doses and with mixed use with alcohol or other substances. Reagent testing is important as 4-FA is sometimes misrepresented as MDMA.
Safety at a Glance
High Risk- Test Your Substance
- This is critical for 4-FA:
- Toxicity: Cardiovascular Risk — Serious Concern 4-FA's most serious documented risk is cardiovascular. The Dutch epidemiologica...
- Dangerous with: Atropa belladonna, Datura, Diphenhydramine, Harmala alkaloid, 25x-NBOMe, 2C-T-x, DOx (+2 more)
- Overdose risk: LD50 (mouse; i.p.) of 4-FA is 46 mg/kg. 4-FA does not cause long-lasting depletion of brain serot...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 5 hrs – 8 hrsHow It Feels
The onset of 4-FA unfolds in two distinct chapters. The first thirty to sixty minutes bring a conventional stimulant rise: increasing alertness, mental clarity, a quickening pulse, and a mild optimism. Then, somewhere around the sixty- to ninety-minute mark, the second chapter begins. A warm, rolling wave of euphoria and empathogenic openness crests and breaks, flooding the body with a serotonergic glow that fundamentally changes the character of the experience. The transition from stimulant to entactogen is often vivid and unmistakable, and it is this dual nature that has earned 4-FA its reputation.
At its empathogenic peak, roughly two to three hours after ingestion, 4-FA produces a state of emotional openness and interpersonal warmth that many compare to MDMA. Conversations deepen effortlessly, emotional barriers soften, and there is a genuine, heartfelt affection for the people around you that feels neither manufactured nor naive. Touch becomes luxuriously pleasurable. Music acquires emotional gravity and physical presence. The stimulant backbone keeps the mind sharp and the body energized even as the empathogenic component dissolves social anxiety and self-consciousness. The combination is potent: lucid, warm, confident, and deeply sociable.
Physically, the effects are significant. Heart rate and blood pressure rise substantially. The jaw clenches with persistent force. Pupils dilate widely. Body temperature increases, and sweating is common even at rest. Appetite is abolished. There is a buzzing, restless energy in the muscles that encourages movement, and many users find dancing or physical activity deeply satisfying during the peak. The body load is real but tends to be overshadowed by the intensity of the subjective experience.
The decline is gradual, beginning around four to five hours in. The empathogenic warmth fades first, retreating like a tide and leaving behind the stimulant skeleton: clean alertness without the emotional richness. This secondary phase can last another three to four hours, during which focus and energy persist but the magic has clearly passed. The comedown, when it finally arrives, carries a serotonergic weight. Fatigue, emotional flatness, and a subdued quality mark the following day or two. The more the serotonergic peak was enjoyed, the more the subsequent depletion is felt, a familiar exchange for anyone acquainted with empathogenic compounds.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(27)
- Abnormal heartbeat— Abnormal heartbeat (arrhythmia) is any deviation from the heart's normal rhythm — including beats th...
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Bodily control enhancement— Bodily control enhancement is the subjective feeling of improved physical precision, coordination, a...
- Body load— A diffuse, heavy physical discomfort involving tension, pressure, and malaise in the torso and limbs...
- Brain zaps— Brain zaps are sudden, brief, electrical shock-like sensations that originate in the head and someti...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Difficulty urinating— Difficulty urinating, also known as urinary retention, is the experience of being unable to easily p...
- Dry mouth— A persistent, uncomfortable reduction in saliva production causing the mouth and throat to feel parc...
- Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased bodily temperature— Increased bodily temperature (hyperthermia) is an elevation of core body temperature above the norma...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
- Nystagmus— Rapid, involuntary oscillating movements of the eyes that cause vision to vibrate and blur, often ma...
- Orgasm suppression— Orgasm suppression (anorgasmia) is the difficulty or complete inability to achieve orgasm despite ad...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stamina enhancement— Stamina enhancement is an increase in one's ability to sustain physical and mental exertion over ext...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Teeth chattering— Teeth chattering is an involuntary, rhythmic movement of the jaw that produces rapid clicking or cha...
- Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
- Temperature regulation disruption— Impaired thermoregulation causing unpredictable fluctuations between feeling hot and cold, with risk...
- Temporary erectile dysfunction— Temporary erectile dysfunction is the substance-induced inability to achieve or sustain a penile ere...
- Vibrating vision— Vibrating vision is the subjective experience of the visual field rapidly oscillating or shaking due...
Tactile(1)
- Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...
Cognitive & Perceptual Effects
Visual(2)
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
Cognitive(24)
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Anxiety suppression— A partial to complete suppression of anxiety and general unease, producing a calm, relaxed mental st...
- Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
- Cognitive fatigue— Mental exhaustion and difficulty sustaining thought after intense cognitive experiences, common duri...
- Compulsive redosing— An overwhelming, difficult-to-resist urge to continuously take more of a substance in order to maint...
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Delirium— Delirium is a serious and potentially dangerous state of acute mental confusion involving disorienta...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Disinhibition— A marked reduction in social inhibitions, self-consciousness, and behavioral restraint that manifest...
- Ego inflation— Grandiose overconfidence and inflated self-importance, opposite of ego death, commonly produced by s...
- Empathy enhancement— A state of intensified compassion and emotional openness in which one feels deeply connected to othe...
- Focus enhancement— An enhanced ability to direct and sustain attention on a single task or stimulus with unusual clarit...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Increased sense of humor— A general amplification of one's sensitivity to finding things humorous and amusing, often causing p...
- Irritability— Irritability is a sustained state of emotional reactivity in which the threshold for annoyance, frus...
- Motivation enhancement— A heightened sense of drive, ambition, and willingness to accomplish tasks, making productive effort...
- Motivation suppression— Motivation suppression is a state of diminished drive and willingness to engage in goal-directed beh...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Suicidal ideation— Suicidal ideation is the emergence of thoughts, urges, or preoccupations centered on ending one's ow...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
- Thought disorganization— Thought disorganization is a cognitive impairment in which the normal capacity for structured, seque...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Transpersonal(1)
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
Mechanism of Action
4-FA acts as a potent releasing agent and reuptake inhibitor at all three monoamine transporters — DAT, NET, and SERT — but with relative potencies at SERT significantly higher than the 2- and 3-position isomers. The para substitution appears to optimally position the fluorine atom to interact with the SERT binding site, substantially increasing serotonin releasing activity. This increased serotonergic activity is responsible for the entactogenic effects that distinguish 4-FA from other fluoroamphetamines.
The dose-dependent shift from stimulant to entactogen reflects the interplay between catecholaminergic and serotonergic systems: at lower doses, dopamine/norepinephrine effects dominate (focus, energy, mild euphoria); at higher doses, the serotonin release becomes more behaviorally prominent (empathy, emotional openness, sensory enhancement).
Receptor Profile
- SERT — High serotonin releasing activity; primary driver of entactogenic effects
- DAT — Significant dopamine releasing activity; stimulation and euphoria
- NET — Norepinephrine release; cardiovascular activation, wakefulness
- 5-HT2A — Indirect activation via serotonin; contributes to mild perceptual effects
Pharmacokinetics
- Onset: 30–60 minutes oral
- Peak: 2–3 hours
- Duration: 5–7 hours (distinctly longer than MDMA, shorter than 2-FMA)
- Total: 7–10 hours including aftereffects
The para-fluorine substitution increases metabolic stability relative to amphetamine, contributing to extended duration.
Neurotoxicity Research
Animal studies on para-fluoroamphetamine analogs have documented serotonergic axonal damage following high-dose administration — consistent with the established neurotoxicity mechanism of MDMA. While the doses required are substantially higher than typical human doses, the risk is relevant for users taking high doses or dosing frequently.
Detection Methods
Standard Drug Panel Inclusion
4-FA (4-Fluoroamphetamine) is a fluorinated amphetamine analogue that is generally not detected on standard 5-panel, 10-panel, or 12-panel immunoassay drug screens. The fluorine substitution on the phenyl ring alters the molecular structure sufficiently that most amphetamine-targeted antibodies in commercial immunoassays fail to recognize it. However, cross-reactivity varies between manufacturers and assay generations, so a false positive on the amphetamine channel cannot be entirely ruled out.
Urine Detection
Due to the structural similarity to amphetamine, 4-FA (4-Fluoroamphetamine) and its metabolites may persist in urine for approximately 2 to 4 days after a single dose. Chronic or heavy use can extend this window. The primary metabolites include deaminated and hydroxylated derivatives, though comprehensive metabolic profiling of 4-FA (4-Fluoroamphetamine) in humans remains limited. Standard immunoassay urine cups will typically return a negative result for 4-FA (4-Fluoroamphetamine) unless the specific assay has unusually broad cross-reactivity.
Blood and Saliva Detection
4-FA (4-Fluoroamphetamine) can be detected in blood and oral fluid for approximately 12 to 48 hours after ingestion. Blood testing is uncommon outside of clinical or forensic contexts. Oral fluid testing follows a similar window but is used primarily in roadside or workplace settings where immediate-use detection is the goal.
Hair Follicle Detection
Hair follicle analysis can theoretically detect 4-FA (4-Fluoroamphetamine) for up to 90 days. However, most commercial hair testing laboratories do not include fluorinated amphetamines in their standard panels. Detection requires specific method development using LC-MS/MS with reference standards for 4-FA (4-Fluoroamphetamine).
Confirmatory Testing
Gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) are the definitive methods for confirming the presence of 4-FA (4-Fluoroamphetamine). These techniques can distinguish 4-FA (4-Fluoroamphetamine) from amphetamine, methamphetamine, and other substituted amphetamines with high specificity. Reference standards for 4-FA (4-Fluoroamphetamine) must be available to the testing laboratory for positive identification.
Reagent Testing
Marquis reagent produces no reaction or a faint orange-brown color with 4-FA (4-Fluoroamphetamine), which differs from the orange-to-brown response seen with standard amphetamine. Mecke reagent typically shows no reaction. Simon's reagent can help differentiate primary amines from secondary amines in the amphetamine class. Mandelin reagent may produce a faint green-brown color. These reagent responses help distinguish 4-FA (4-Fluoroamphetamine) from MDMA, methamphetamine, and cathinones but cannot confirm identity on their own.
Interactions
| Substance | Status | Note |
|---|---|---|
| Atropa belladonna | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Datura | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Diphenhydramine | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Harmala alkaloid | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Peganum harmala | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| 25x-NBOMe | Unsafe | — |
| 2C-T-x | Unsafe | — |
| DOx | Unsafe | — |
| PCP | Unsafe | — |
| 1,3-Butanediol | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 25E-NBOH | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-2 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-21 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Alcohol | Uncertain | — |
| Caffeine | Uncertain | — |
| Cannabis | Uncertain | — |
| Cocaine | Uncertain | — |
| GBL | Uncertain | — |
History
Pre-Market History
4-Fluoroamphetamine has appeared in the pharmacological literature as a research compound, primarily studied in the context of serotonergic neurotoxicity models and as a tool for understanding fluorine substitution effects on monoamine transporter binding. Its entactogenic properties were characterized in receptor binding and behavioral studies in animals.
Dutch Market Dominance
4-FA had a prolonged period of legal status in the Netherlands despite MDMA being illegal, making it uniquely accessible in Dutch recreational drug markets. It was widely sold in Dutch smart shops and online vendors and became embedded in Dutch party and festival culture. Surveys estimated millions of uses without the adverse event rate becoming apparent, as early users did not encounter the same conditions or doses that later led to harm.
The 2017–2018 Crisis
A cluster of serious adverse events in the Netherlands in 2017 — including cases of cerebral hemorrhage attributed to hypertensive crisis — prompted public health warnings and ultimately emergency scheduling by the Dutch government in May 2017. Subsequent analysis implicated dose, alcohol combinations, and physical exertion as major risk factors. 4-FA was formally prohibited in the Netherlands in 2017.
Legacy
4-FA's Dutch experience represents one of the most detailed real-world pharmaco-epidemiological case studies in research chemical harm. It established that a "gentler MDMA alternative" could produce its own serious adverse event cluster under specific conditions, and it has informed subsequent regulatory and community harm reduction approaches to entactogenic research chemicals.
Harm Reduction
Test Your Substance
This is critical for 4-FA:
- Marquis reagent: 4-FA turns yellow to orange (contrast with MDMA's purple-black)
- Mecke reagent: blue-black with MDMA; different response with 4-FA
- Fentanyl test strip: essential to rule out contamination
Dose Reference
- Stimulant range: 50–100 mg oral (more amphetamine-like effects)
- Entactogenic range: 100–175 mg oral (MDMA-adjacent effects emerge)
- Do not exceed 175 mg; the cardiovascular risk increases sharply at higher doses
- The Dutch adverse events disproportionately involved doses in the 150–250+ mg range
Alcohol Is a Serious Risk Amplifier
Community harm reduction specifically for 4-FA: do not combine with alcohol. The cardiovascular and hypertensive event risk documented in the Dutch cases was substantially associated with concurrent alcohol use. This is a major risk factor specific to 4-FA and is more strongly emphasized for this compound than for MDMA.
Avoid Redosing
Unlike MDMA, 4-FA's 5–7 hour duration means redosing during a session is almost never necessary. Redosing substantially increases cardiovascular risk.
Use the 3-Month Rule
Given the serotonergic neurotoxicity profile, apply MDMA-style recovery intervals: minimum 1–3 months between uses to allow serotonergic and cardiovascular recovery.
Monitoring in Settings
In recreational settings, monitor for hypertension, severe headache, visual changes — early signs of hypertensive crisis requiring immediate medical attention.
Toxicity & Safety
Cardiovascular Risk — Serious Concern
4-FA's most serious documented risk is cardiovascular. The Dutch epidemiological experience (2017–2018) produced multiple cases of intracerebral hemorrhage, hypertensive crisis, and death linked to 4-FA use. Analysis suggested that the compound's combination of dopamine, norepinephrine, AND serotonin releasing activity — when combined with physical exertion, alcohol, or other substances — produced acute hypertensive events exceeding the risk of MDMA used in comparable settings.
The cardiovascular risk is dose-dependent and scales dramatically with redosing. Do not combine with alcohol, MDMA, other stimulants, or vasoconstrictors.
Serotonergic Neurotoxicity
At high doses or with frequent heavy use, 4-FA carries serotonin neurotoxicity risk comparable to MDMA. Animal studies on fluoroamphetamines document serotonergic axon terminal degeneration. Use frequency should mirror MDMA harm reduction principles.
Hyperthermia
In combination with physical exertion (dancing, exercise) and inadequate hydration, 4-FA can produce dangerous hyperthermia. This was a contributing factor in several Dutch adverse event cases.
Drug Interaction Risk
- MAOIs — Fatal; absolute contraindication
- SSRIs — Potential serotonin syndrome; SSRIs will also blunt entactogenic effects
- Alcohol — Major risk amplifier; dramatically increases cardiovascular hazard
- MDMA/other entactogens — Doubled serotonergic load; additive neurotoxicity risk
Adulterant Risk
4-FA is sometimes sold as MDMA or mixed with MDMA. Test with Marquis reagent (turns yellow-orange with 4-FA, rather than purple-black with MDMA) and ideally fentanyl test strips.
Addiction Potential
moderately addictive with a high potential for abuse
Overdose Information
LD50 (mouse; i.p.) of 4-FA is 46 mg/kg. 4-FA does not cause long-lasting depletion of brain serotonin unlike MDMA or 4-FA's analogs 4-CA and 4-BA.
It is also worth noting that 4-FA is particularly caustic in comparison to other compounds and can, therefore, cause chemical burns within the nasal passage and throat if it is insufflated. This method of administration is discouraged.
It is strongly recommended that one use harm reduction practices when using this substance.
As with other stimulants, the chronic use of 4-moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.
Tolerance to many of the effects of 4-develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that,3 - 71 - 2 weeks to be back at baseline (in the absence of further consumption). This is how long it takes to reduce the tolerance for the stimulating effects. Tolerance for the entactogenic effects may take a longer period to reduce. 4-FA presents cross-tolerance with Cross-all dopaminergic stimulants, meaning that after the consumption of 4-FA all stimulants will have a reduced effect.
4-FA, like other stimulants, can result in a stimulant psychosis that may present with a variety of symptoms (e.g., paranoia, hallucinations, or delusions). A review on treatment for amphetamine, dextroamphetamine, and methamphetamine abuse-induced psychosis states that about 5–15% of users fail to recover completely. The same review asserts that, based upon at least one trial, antipsychotic medications effectiv
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Tolerance
| Full | develops with prolonged and repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
Austria: 4-FA is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).
Brazil: 4-FA is illegal to possess, produce and sell as it is listed on Portaria SVS/MS nº 344.
Canada: 4-FA would fall under Schedule I as it is considered an analog of amphetamine.
France: 4-FA is scheduled as a "stupéfiant", i.e. a recognized drug of abuse. It is illegal to possess, buy, sell or manufacture.
Germany: 4-FA is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of July 26, 2012. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Hungary: In January 2012, 4-FA became controlled in Hungary.
Israel: In December 2007, 4-FA was added to Israel's list of controlled substances, making it illegal to buy, sell, or possess.
The Netherlands: 4-FA is a Schedule 1 drug in the Netherlands as of May 25th 2017.
New Zealand: 4-FA is an amphetamine analogue, so is a Schedule 3 controlled substance in New Zealand.
Poland: 4-FA is controlled in Poland.
Slovak Republic: Beginning March 1, 2011, 4-Fluoroamphetamine is controlled in the Slovak Republic.
Switzerland: 4-FA is a controlled substance specifically named under Verzeichnis D.
Turkey:** 4-FA is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom: 4-FA is considered a Class A drug as a result of the amphetamine analogue clause of the Misuse of Drugs Act 1971.
United States: 4-FA is not scheduled on a federal level in the United States.
Arizona: 4-FA was added to the "Dangerous Drug" list in April 2014.
Louisiana: 4-FA is currently listed as a Schedule I drug as of June 2013.
Virginia: 4-FA is classified as a Schedule I drug.
Responsible use
Research chemical
Stimulants
Amphetamine
4-FA (Wikipedia)
4-FA (Erowid Vault)
4-FA (Isomer Design)
Discussion
Big n Dandy 4-FA (4-fluoroamphetamine) thread v.1.0 (Bluelight)
Tips (6)
4-FA has been linked to strokes and serious cardiovascular events in the Netherlands. Do not use if you have any history of heart problems, high blood pressure, or family history of stroke. Monitor your blood pressure if possible.
Stay hydrated while using 4-FA. Stimulants increase heart rate and body temperature while suppressing thirst signals. Sip water regularly, roughly 250-500ml per hour, more if dancing or in hot environments.
4-FA is considered the gold standard for empathogenic stimulants at doses above 100mg. Below 100mg it functions as a clean stimulant. The empathogenic effects at higher doses are frequently compared to MDMA but with more stimulation and less sedation.
Avoid binge patterns with 4-FA. Sleep deprivation combined with stimulant use dramatically increases psychosis risk after 48+ hours awake. If you find yourself redosing to avoid the comedown, that is a major warning sign.
Weigh your dose of 4-FA with a milligram scale. Street stimulants vary wildly in purity and potency. What looks like a normal amount could be significantly stronger than expected, especially with a new batch.
Space 4-FA use at least 4-6 weeks apart due to its serotonergic activity at empathogenic doses. Using the same spacing guidelines as MDMA (minimum 1 month, ideally 3 months) is prudent for neurotoxicity prevention.
See Also
References (4)
- Amphetamine: new content for an old topic — Heal et al. Neuropsychopharmacology Reviews (2013)paper
- MDMA-assisted therapy for PTSD — Mithoefer et al. Psychopharmacology (2019)paper
- 4-FA - TripSit Factsheet
TripSit factsheet for 4-FA
tripsit - 4-FA - Wikipedia
Wikipedia article on 4-FA
wikipedia